Feldan Therapeutics is pleased to share the promising results of FLD103 to treat basal cell carcinoma. A poster presented at the WCH23 Dermatology Conference last January (Intralesional Treatment of Basal Cell Carcinoma in a Genetically Inducible Mouse Model) has just been published in Skin-The Journal of Cutaneous Medicine! https://jofskin.org/index.php/skin/article/view/1971